Adma Biologics (ADMA) Raw Materials (2016 - 2026)
Adma Biologics' (ADMA) quarterly Raw Materials came in at $96.6 million in Q4 2025, up 59.76% YoY from $60.5 million in Q4 2024, and up 9.99% on a QoQ basis from $87.8 million in Q3 2025.
Adma Biologics (ADMA) Raw Materials (2016 - 2026) Analysis & Trends
Adma Biologics (ADMA) has 10 years of Raw Materials data on file, last reported at $96.6 million in Q4 2025.
- Quarterly Raw Materials rose 59.76% year-over-year to $96.6 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $96.6 million (up 59.76% YoY) and the FY2025 annual result came in at $96.6 million, up 59.76% from the prior year.
- Raw Materials grew to $96.6 million in Q4 2025, from $87.8 million in the prior quarter.
- In the past five years, Raw Materials ranged from a high of $100.4 million in Q2 2025 to a low of $33.1 million in Q2 2021.
- A 5-year average of $57.4 million and a median of $53.0 million in 2023 frame the typical range for Raw Materials.
- Annual changes were most pronounced in 2023 — Raw Materials grew 4.35% — and 2025, when it jumped 76.14%.
- Tracing ADMA's Raw Materials over 5 years: stood at $36.8 million in 2021, then jumped by 32.34% to $48.6 million in 2022, then climbed by 8.95% to $53.0 million in 2023, then grew by 14.1% to $60.5 million in 2024, then surged by 59.76% to $96.6 million in 2025.
- The last three Raw Materials figures came in at $96.6 million (Q4 2025), $87.8 million (Q3 2025), and $100.4 million (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Adma Biologics | 2.13 Bn | 2.00 Bn | 86.28 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 94.30 Mn |
| Dec 31, 2025 | 96.61 Mn |
| Sep 30, 2025 | 87.84 Mn |
| Jun 30, 2025 | 100.37 Mn |
| Mar 31, 2025 | 75.82 Mn |
| Dec 31, 2024 | 60.47 Mn |
| Sep 30, 2024 | 55.25 Mn |
| Jun 30, 2024 | 56.99 Mn |
| Mar 31, 2024 | 59.46 Mn |
| Dec 31, 2023 | 53.00 Mn |
| Sep 30, 2023 | 49.86 Mn |
| Jun 30, 2023 | 50.00 Mn |
| Mar 31, 2023 | 55.75 Mn |
| Dec 31, 2022 | 48.64 Mn |
| Sep 30, 2022 | 47.78 Mn |
| Jun 30, 2022 | 38.32 Mn |
| Mar 31, 2022 | 46.03 Mn |
| Dec 31, 2021 | 36.76 Mn |
| Sep 30, 2021 | 37.93 Mn |
| Jun 30, 2021 | 33.06 Mn |